Semaglutide, tirzepatide and retatrutide: differences
Semaglutide, tirzepatide and retatrutide act on hormone receptors involved in metabolism. Their shared research area does not make them interchangeable.
What is each compound?
- Semaglutide: a GLP-1 receptor agonist.
- Tirzepatide: a dual GIP and GLP-1 receptor agonist.
- Retatrutide: an investigational triple GIP, GLP-1 and glucagon receptor agonist.
Are Ozempic and Mounjaro the same?
Ozempic contains semaglutide; Mounjaro contains tirzepatide. Formulated medicines containing these ingredients have specific approved indications in the United States. That does not establish registration of a presentation in Ecuador or make research vials equivalent medicines. Check local registration and consult a licensed professional.
What a direct comparison shows
In SURMOUNT-5, adults with obesity without diabetes had mean weight changes of −20.2% with tirzepatide and −13.7% with semaglutide over 72 weeks under the trial conditions. Group averages do not predict individual outcomes or validate ZENOVA materials. Read the 2025 trial.
Where does retatrutide fit?
Retatrutide has a developing clinical evidence base. Results from separate trials cannot establish superiority over the other compounds: populations, duration, design and analyses differ. Lilly identifies retatrutide as investigational and unapproved.
Adverse effects and clinical decisions
These medicine families can cause gastrointestinal adverse effects and have product-specific precautions. Questions about Mounjaro side effects belong with the exact medicine label and treating clinician. This article does not establish doses, combinations or treatment changes. FDA information on tirzepatide.
Research documentation in Ecuador
ZENOVA materials are for research only, not human or animal administration. Check identity, lot, analytical methods and documented storage conditions. Purity alone does not demonstrate sterility or clinical suitability.
Read the semaglutide, tirzepatide and retatrutide pages, our COA guide, and the plateau evidence review.